The stock of Lineage Cell Therapeutics Inc (AMEX:LCTX) last traded at $0.60, down -6.45% from the previous session.
LCTX stock price is now -31.42% away from the 50-day moving average and -40.76% away from the 200-day moving average. The market capitalization of the company currently stands at $113.30M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $4, Craig Hallum recently initiated with Buy rating for Lineage Cell Therapeutics Inc (AMEX: LCTX). On November 02, 2022, Robert W. Baird recently initiated its ‘Outperform’ rating on the stock quoting a target price of $5, while ‘B. Riley Securities’ rates the stock as ‘Buy’
In other news, Howe Jill Ann, Chief Financial Officer bought 10,500 shares of the company’s stock on Aug 16 ’24. The stock was bought for $9,345 at an average price of $0.89. Upon completion of the transaction, the Chief Financial Officer now directly owns 10,500 shares in the company, valued at $6300.0. An SEC document containing details of the transaction can be found on the SEC’s website. On May 24 ’24, President and CEO Culley Brian M bought 10,000 shares of the business’s stock. A total of $10,500 was incurred on buying the stock at an average price of $1.05. This leaves the insider owning 154,842 shares of the company worth $92905.2. A total of 0.44% of the company’s stock is owned by insiders.
During the past 12 months, Lineage Cell Therapeutics Inc has had a low of $0.61 and a high of $1.61. As of last week, the company has a debt-to-equity ratio of 0.04, a current ratio of 2.48, and a quick ratio of 2.48. The fifty day moving average price for LCTX is $0.8812 and a two-hundred day moving average price translates $1.01525 for the stock.
The latest earnings results from Lineage Cell Therapeutics Inc (AMEX: LCTX) was released for 2024-06-30. The net profit margin was -230.66% and return on equity was -29.95% for LCTX. The company reported revenue of $3.78 million for the quarter, compared to $1.25 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 203.29 percent.
